Skip to main content
. 2020 Aug 24;58(10):919–926. doi: 10.1097/MLR.0000000000001394

TABLE 3.

Unadjusted Per Member Per Month Costs After Initiation of Treatment by Cumulative Duration of Buprenorphine/Methadone or Naltrexone Treatment Over 12 Months of Contiguous Enrollment

Unadjusted Mean Cost Per Member Per Month [Mean (SD)] ($)
Cumulative Duration on n (%) Baseline Follow-up Unadjusted Within Group Cost Ratio
Buprenorphine/methadone (d)
 0 17,606 (83) 3366 (7663) 3360 (6132) 1.00
 1–30 738 (3.5) 2094 (5363) 3332 (5488) 1.59
 31–180 1127 (5.3) 2037 (6608) 2847 (5051) 1.40
 >180 1729 (8.2) 1356 (3256) 1973 (2631) 1.46
Naltrexone (d)
 0 19,900 (93.9) 3104 (7407) 3123 (5824) 1.01
 1–30 567 (2.7) 2474 (4523) 4361 (6136) 1.76
 31–180 574 (2.7) 3116 (6321) 4898 (6012) 1.57
 >180 159 (0.8) 3156 (5405) 5023 (7129) 1.59